Does Additional Laparoscopic-Assisted Surgery after Endoscopic Submucosal Dissection Affect Short Outcomes in Patients with Stage T1 Colorectal Cancer? A Propensity Score-Based Analysis

Abstract

<b><i>Background:</i></b> Additional surgery is necessary in cases with non-curative endoscopic submucosal dissection. It is still unknown whether preceding endoscopic submucosal dissection (ESD) for T1 colorectal carcinoma affects the short outcomes of patients who underwent additional surgery or not as compared with surgery alone without ESD. <b><i>Methods:</i></b> Patients (101 pairs) with T1 colorectal cancer who underwent additional laparoscopic-assisted surgery after endoscopic submucosal dissection (additional surgery group, <i>n</i> = 101) or laparoscopic-assisted surgery alone (surgery alone group, <i>n</i> = 101) were matched (1:1). Short-term morbidity, operation outcomes, and lymph node metastasis of the resected specimen were compared. <b><i>Results:</i></b> There were no significant differences between the additional laparoscopic-assisted surgery and laparoscopic-assisted surgery alone groups in lymph node metastasis (9.9 vs. 5.9%, respectively, <i>p</i> = 0.297), operative time (147.76 ± 52.00 min vs. 156.50 ± 54.28 min, <i>p</i> = 0.205), first flatus time (3.56 ± 1.10 days vs. 3.63 ± 1.05 days, <i>p</i> = 0.282), first stool time (4.30 ± 1.04 days vs. 4.39 ± 1.22 days, <i>p</i> = 0.293), time to intake (5.00 ± 1.18 days vs. 5.25 ± 1.39 days, <i>p</i> = 0.079), blood loss (44.75 ± 45.40 mL vs. 60.40 ± 78.98 mL, <i>p</i> = 0.603), harvest lymph nodes (18.74 ± 7.22 vs. 20.32 ± 9.69, <i>p</i> = 0.438), postoperative surgical complications (<i>p</i> = 0.733), and postoperative length of hospital stay (8.68 ± 4.00 days vs. 8.39 ± 1.94 days, <i>p</i> = 0.401). <b><i>Conclusion:</i></b> ESD did not increase the difficulty of additional laparoscopic-assisted surgery, hospital stay, or the incidence of postoperative complications. Additional laparoscopic-assisted surgery is safe and recommended for patients with T1 cancer at high risk of lymph node metastasis and residual cancer after non-curative ESD.